Benzinga | Mar 2, 2021 09:12AM EST

ObvioHealth And RedHill Announce Launch O Trial For ObvioHealth and RedHill

NEW YORK, March 2, 2021 /PRNewswire/ -- ObvioHealth, a global virtual research organization or VRO, today announced the launch of a hybrid clinical trial for the treatment of COVID-19, using an innovative study design with digital data capture to remotely monitor patient vitals. This U.S. Phase 2/3 study will examine the safety and efficacy of RedHill Biopharma's (NASDAQ:RDHL) RHB-107 (upamostat), using ObvioHealth's clinical trial ecosystem, including digital devices, a patient-centric smartphone application and home healthcare visits.